Terray Therapeutics
Terray Therapeutics, founded in 2022, leverages AI to accelerate small molecule drug discovery, supported by a vast experimental dataset and rapid design-make-test-analyze cycles.
Company Overview
Terray Therapeutics was founded in 2022 with initial funding of $60 million to advance AI-driven small molecule drug discovery. The company utilizes a sophisticated platform designed to improve the speed, cost, and success rate of small molecule drug discovery and development. Terray Therapeutics focuses on integrating chemical experimentation with computational processes to facilitate generative AI-driven drug discovery on an unprecedented scale.
Technological Capabilities
Terray Therapeutics leverages an experimental dataset that includes over two billion unique target-ligand binding measurements, expanding by 150 million new measurements each month. Each measurement benefits from an average of 25 independent data points, allowing the company to predict molecular properties accurately using deep learning regression models. This approach facilitates an efficient design-make-test-analyze cycle, which takes less than a month per target.
Focus Areas and Collaborations
Terray Therapeutics has an internal pipeline that primarily focuses on immunology and extends to various therapeutic areas through partnerships with large pharma and biotech companies. In December 2023, the company announced a multi-target collaboration with Bristol Myers Squibb, highlighting its commitment to advancing therapeutic discoveries through strategic alliances.
Recent Investments and Innovations
In November 2023, Terray Therapeutics received an investment from NVIDIA to enhance its generative AI design capabilities for drug discovery. This investment signifies the company's ongoing efforts to integrate advanced technological innovations into its research and development processes, further cementing its position in the AI-driven drug discovery sector.